Compositions and methods for cell reprogramming using circular RNA
Through the synergy of the four circular RNAs, the problem of slow cell reprogramming process and low success rate is solved, and efficient induction of somatic cells into pluripotent stem cells is achieved, which significantly improves the re-editing efficiency and has commercial application potential.
Patent Information
- Application Number
- CN202411437484.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2025-01-10
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, the cell reprogramming process is slow and the success rate is low. In particular, the technology of using small molecules to achieve re-editing needs to be improved, making it difficult to efficiently induce somatic cells to dedifferentiate into pluripotent stem cells.
The mixture of four specific circular RNAs (hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884, hsa_circ_0010993) was used to synergistically, and by transfecting fibroblasts, they were induced to reprogram into induced pluripotent stem cells, increasing the number of iPSCs colonies and Oct4, Sox2, c - Expression of Myc, Klf4 transcription factor.
It significantly improves the efficiency and success rate of somatic cell reprogramming, can quickly and efficiently induce a large number of induced pluripotent stem cells in vitro, the re-editing efficiency is much higher than that of the existing technology, and has good commercial application prospects.
Smart Images

Figure CN119286791A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cell reprogramming, and in particular to a composition and a method for cell reprogramming using circular RNA. Background Art
[0002] At present, reprogramming refers to the process of changing cell fate through epigenetic modifications such as DNA methylation without changing the gene sequence. It originally referred to the process of eliminating the epigenetic marks carried by its parents during the development of mammalian germ cells. Later, it was confirmed that in vitro operations of embryos such as nuclear transplantation and cell fusion can also change their original epigenetic characteristics. At present, reprogramming mainly refers to two processes: first, the process of reversing differentiated cells to restore to a omnipotent state; second, the process of transforming from one differentiated cell to another differentiated cell.
[0003] The in vitro induction of pluripotent stem cells usually uses a series of induction factors to be introduced into mature somatic cells and re-edited into a type of pluripotent stem cells with characteristics similar to embryonic stem cells. However, the induction process of this type of method is extremely slow and the success rate is extremely low, which is not conducive to industrial application. The technology of using small molecules to achieve re-editing has long been reported by Deng Hongkui's research group. Although its effective efficiency has been improved, the cell biosafety needs to be further improved. Therefore, it is necessary to focus on discovering biological molecules related to somatic cell dedifferentiation and achieve high-efficiency re-editing through fine-tuning of biological molecules. Summary of the invention
[0004] In view of the technical problems existing in the prior art, the present invention provides a composition and method for cell reprogramming using circular RNA. The present invention first discovered that a mixture of four circular RNAs can induce fibroblasts to be reprogrammed into induced pluripotent stem cells, and there is a synergistic effect between the four circular RNAs. The statistics of positive iPSCs colonies under combined transfection are significantly increased, and the expression levels of induced Oct4, Sox2, c-Myc and Klf4 transcription factors are also significantly increased. It is further confirmed that the reprogramming efficacy of the four circular RNA mixtures of the present invention can be used to achieve the reprogramming of somatic cells.
[0005] One of the objects of the present invention is to provide a composition for reprogramming fibroblasts into induced pluripotent stem cells, the composition comprising a combination of one or more of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884, and hsa_circ_0010993.
[0006] Preferably, the composition includes a combination of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993.
[0007] Preferably, the molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition is (1-3):(2-4):(1-3):(3:7).
[0008] Further preferably, the molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition is 1:2:1:3.
[0009] Further preferably, the molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition is 2:3:2:5.
[0010] Further preferably, the molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition is 3:4:3:7.
[0011] On the other hand, the present invention also provides a method for preparing a composition for reprogramming induced pluripotent stem cells from fibroblasts, the method comprising the following steps: adding circular RNA with a final concentration of 100-300 μg / mL to RNase-free ddH2O, wherein the composition contains hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993, and the molar ratio thereof is (1-3):(2-4):(1-3):(3:7).
[0012] Preferably, the method comprises the following steps: adding circular RNA with a final concentration of 100 μg / mL in RNase-free ddH2O, wherein the composition contains hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993, and the molar ratio thereof is 1:2:1:3.
[0013] Preferably, the method comprises the following steps: adding circular RNA with a final concentration of 200 μg / mL in RNase-free ddH2O, wherein the composition contains hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993, and the molar ratio thereof is 2:3:2:5.
[0014] Preferably, the method comprises the following steps: adding circular RNA with a final concentration of 300 μg / mL in RNase-free ddH2O, wherein the composition contains hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993, and the molar ratio thereof is 3:4:3:7.
[0015] On the other hand, the present invention also provides a method for rapidly obtaining induced pluripotent stem cells, comprising the following steps:
[0016] 1) Providing human adult cells;
[0017] 2) inoculating the human adult cells in the basal culture medium containing the circular RNA mixture, culturing continuously for 7-14 days, and replacing fresh culture medium every other day;
[0018] 3) collecting the cells cultured in step 2) by centrifugation, and using flow cytometry and RT-PCR to sort and identify the gene expressions of Oct4, Sox2, c-Myc and Klf4 in the induced cells;
[0019] 4) The results of flow cytometry and RT-PCR were used to identify the induced pluripotent stem cells obtained.
[0020] Preferably, the sequences of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 are shown in SEQ ID No.1-4 respectively.
[0021] The advantages of the present invention are as follows: The present invention first discovered that a mixture of four circular RNAs, hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993, can induce fibroblasts to be reprogrammed into induced pluripotent stem cells, and there is a synergistic effect between the four circular RNAs. The number of positive iPSCs colonies under combined transfection is significantly increased, and the expression levels of induced Oct4, Sox2, c-Myc and Klf4 transcription factors are also significantly increased. It is further confirmed that the reprogramming efficacy of the four circular RNA mixtures of the present invention can be used to achieve the reprogramming of somatic cells. Compared with compound-induced reprogramming, the method of the present invention can quickly and efficiently induce a large number of induced pluripotent stem cells in vitro, and the re-editing efficiency is much higher than the re-editing methods currently known in the prior art, and has good commercial application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 .Statistical number of positive iPSCs colonies induced by the circular RNA mixture;
[0023] Figure 2 .Analysis of the expression of Oct4, Sox2, c-Myc and Klf4 transcription factors induced by circular RNA mixture. DETAILED DESCRIPTION
[0024] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand the present invention more clearly.
[0025] The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Based on the specific embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work belong to the protection scope of the present invention.
[0026] In the examples of the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art; in the examples of the present invention, unless otherwise specified, the technical means used are conventional means well known to those skilled in the art.
[0027] Example 1
[0028] A composition for reprogramming induced pluripotent stem cells from fibroblasts, comprising a mixture of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884, and hsa_circ_0010993.
[0029] The preparation method of the mixture comprises the following steps: adding circular RNA with a final concentration of 100 μg / mL to RNase-free ddH2O, wherein the molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 is 1:2:1:3.
[0030] Example 2
[0031] A composition for reprogramming induced pluripotent stem cells from fibroblasts, comprising a mixture of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884, and hsa_circ_0010993.
[0032] The preparation method of the mixture comprises the following steps: adding circular RNA with a final concentration of 200 μg / mL to RNase-free ddH2O, wherein the molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 is 2:3:2:5.
[0033] Example 3
[0034] A composition for reprogramming induced pluripotent stem cells from fibroblasts, comprising a mixture of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884, and hsa_circ_0010993.
[0035] The preparation method of the mixture comprises the following steps: adding circular RNA with a final concentration of 300 μg / mL to RNase-free ddH2O, wherein the molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 is 3:4:3:7.
[0036] Comparative Example
[0037] Compared with comparative example 1, comparative examples 1-10 contain the same amount of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 or hsa_circ_0010993 as shown in the following table. Among them, + represents the presence of the substance, and - represents the absence of the substance. The composition of the comparative examples is shown in Table 1.
[0038] Table 2: Composition of comparative examples
[0039]
[0040]
[0041] Verification Example
[0042] 1.1 Fibroblast treatment
[0043] Matrigel 354277 (Corning Inc., NY) diluted 100-fold using DMEM / F12 was added to a 6-well cell culture dish and cultured at 37°C in a 5% CO2 tissue culture incubator for 1 hour; primary human neonatal fibroblasts were plated at a density of 200 to 100,000 cells per well in a 6-well cell culture dish format. Coated culture dish; add culture medium to the 6-well cell culture dish, wherein the culture medium contains DMEM / F12, 10% heat-inactivated FBS, 0.4mM GLUTAMAX TM Supplements; incubate the plated cells overnight in a 5% CO2 tissue culture incubator.
[0044] 1.2 Transfection solution preparation
[0045] The commercially available CALNP liposome transfection reagent was used to prepare the transfection complex. 1.5 μg of the circular RNA in the above examples and comparative examples was added with 15 μL of CALNP A solution and mixed; 4 μL of CALNP B solution was added, mixed, and incubated at room temperature for 10 min; and then 50 μL of reproTSER complete culture medium was added thereto for dispersion, thereby completing the preparation of the circular RNA complex for transfection in one well of a six-well plate.
[0046] 1.3 Transfection
[0047] Transfection was performed every 48 hours. The medium was replaced with ordinary DMEM + 10% FBS for fibroblast culture 24 hours after each transfection in the first 8 days, and then replaced with reproTeSR complete medium after transfection. After completing the four transfection series, the medium was replaced every day (reproTESR medium supplemented with 200ng / mL B18R). The cells were grown to day 12, and the morphological changes of neonatal fibroblasts were detected, and the number of positive iPSCs colonies was counted. The results are shown in Figure 1 .
[0048] Statistical Figure 1 The results showed that under the action of Examples 1-3 of the present invention, neonatal fibroblasts were able to efficiently reprogram fibroblasts into induced pluripotent stem cells compared to Comparative Examples 1-10, and the number of positive iPSCs colonies was significantly higher than that of the Comparative Examples.
[0049] The expression levels of Oct4, Sox2, c-Myc and Klf4 were further detected by qPCR. Figure 2 . Figure 2 The results showed that under the combination of the four circular RNAs of the present invention, the expression levels of the four transcription factors in the transfected cells were significantly increased, suggesting that they have the potential to be reprogrammed into induced pluripotent stem cells.
[0050] The above embodiments are intended to illustrate the essential content of the present invention, but are not intended to limit the protection scope of the present invention. Those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and protection scope of the technical solution of the present invention.
Claims
1. A composition for reprogramming fibroblasts into induced pluripotent stem cells, characterized in that: The composition includes a combination of one or more of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884, and hsa_circ_0010993.
2. The composition according to claim 1, characterized in that The composition includes a combination of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993.
3. The composition according to claim 2, characterized in that The molar amounts of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition are (1-3):(2-4):(1-3):(3:7).
4. The composition according to claim 3, characterized in that The molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition is 1:2:1:
3.
5. The composition according to claim 3, characterized in that The molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition is 2:3:2:
5.
6. The composition according to claim 3, characterized in that The molar ratio of hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in the composition is 3:4:3:
7.
7. A method for preparing a composition for reprogramming fibroblasts into induced pluripotent stem cells, characterized in that: The method comprises the following steps: adding circular RNA with a final concentration of 100-300 μg / mL to RNase-free ddH2O, wherein the composition comprises hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in a molar ratio of (1-3):(2-4):(1-3):(3:7).
8. The method according to claim 7, characterized in that The method comprises the following steps: adding circular RNA with a final concentration of 100 μg / mL to RNase-free ddH2O, wherein the composition comprises hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in a molar ratio of 1:2:1:
3.
9. The method according to claim 7, characterized in that The method comprises the following steps: adding circular RNA with a final concentration of 200 μg / mL to RNase-free ddH2O, wherein the composition comprises hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in a molar ratio of 2:3:2:
5.
10. The method according to claim 7, characterized in that The method comprises the following steps: adding circular RNA with a final concentration of 300 μg / mL to RNase-free ddH2O, wherein the composition comprises hsa_circ_0009125, hsa_circ_0137518, hsa_circ_0122884 and hsa_circ_0010993 in a molar ratio of 3:4:3:7.
Citation Information
Patent Citations
Compositions and methods for cell reprogramming using circular RNA and microRNA
CN118638781A
Compositions and methods for cellular reprogramming using circular RNA
US20230332182A1